We are leaders in the discovery and development of oligonucleotides as therapeutic agents.

This biopharmaceutical development company has proprietary technology that combines the specific targeting of nucleic acids to different types of neurons in order to develop more effective and innovative treatments for diseases of the central nervous system. The company has proven its technology in animal models on morbid obesity, Parkinson’s Disease, and Major Depressive Disorder (MDD).